| answer text |
<p>Pembrolizumab (Keytruda) was licensed on 12 June 2018 by the United States Food
and Drug Administration for use in patients with recurrent or metastatic cervical
cancer with disease progression on or after chemotherapy.</p><p>However, pembrolizumab
is not licensed for the treatment of cervical cancer in the United Kingdom or in the
European Union. To obtain a licence for this indication, the Marketing Authorisation
Holder of Keytruda (Merck Sharp & Dohme B.V.) would need to submit an ‘extension
of indication’ application to the European Medicines Agency including evidence of
safety and efficacy.</p>
|
 |
